Sirolimus Eluting

Stent System

Envisolution Technology

  • ABLUMINAL COATING

    Facilitate mono directional drug release and less systemic exposure of drug leading to faster re-endothelistation

  • FUSION COATING

    Coating on the stent and exposed parts of the balloon facilitate homogenous drug delivery which address diffused proliferative disease and focal restenosis

  • Edge Coating

    The additional 0.5mm coating on the edge of the balloon which addresses the edge restenosis

  • Biodegradable Film

    The formation of circular film with biodegradable polymer facilitate maximum drug delivery in blood wet conditions

Robust And Comprehensive Clinical Programs

MORE THAN 10,000 PATIENTS ENROLED AND PLANNED

Sr. No Study Name Type of Study Target Patients Country Principal Investigator
Sr. No:  01 Study Name:  en-ABL 1 Study Type of Study:  Prospective, Single centre, Non- randomized clinical trial Target Patients:  40 Patients Country:  India Principal Investigator:  Dr. Sameer Dani
Sr. No:  02 Study Name:  en-ABL e-Registry Type of Study:  Multi-center, Prospective, All-comers registry Target Patients:  2,500 patients Country:  India Principal Investigator:  Dr. Sameer Dani
Sr. No:  03 Study Name:  DEDICATE Registry Type of Study:  Prospective, Multi-center, Spontaneous clinical registry Target Patients:  5,000 patients Country:  Global Principal Investigator:  Dr. Luca Testa
Sr. No:  04 Study Name:  ABILITY RCT Type of Study:  Multi-centre, Single-blinded, Randomized, Investigator-initiated pilot clinical study Target Patients:  165 patients Country:  Italy Principal Investigator:  Dr. Azeem Latib,
Dr. Antonio Colombo
“Confidence through evidence”
Get in Touch
Download Clinical Update